Safety, Tolerability and Pharmacokinetics of AZD1775 (Adavosertib) Plus MEDI4736 (Durvalumab) in Patients With Advanced Solid Tumours

PHASE1Active, not recruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

December 28, 2015

Primary Completion Date

April 22, 2019

Study Completion Date

December 31, 2025

Conditions

Advanced Solid Tumours

Interventions

DRUG

AZD1775

AZD1775 (adavosertib) is available in capsules for oral administration.

DRUG

MEDI4736

MEDI4736 (durvalumab) will be administered by IV infusion.

Trial Locations (3)

Research Site, Sarasota

Research Site, Nashville

Research Site, Denver